FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
The Pharma Data
JUNE 28, 2023
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency NEW YORK & MIAMI–(BUSINESS WIRE)– Pfizer Inc. 1,2 Without treatment, children will have persistent growth attenuation, a very short height in adulthood, and puberty may be delayed.
Let's personalize your content